Uterine Fibroids: Symptoms, Diagnosis, Treatment & Bleeding Care

Uterine leiomyomas are benign clonal neoplasms of uterine smooth muscle interlaced with fibrous stroma. They express oestrogen and progesterone receptors, which explains growth during the reproductive years, enlargement in pregnancy, and involution after menopause. Pathophysiology links to abnormal extracellular matrix deposition, dysregulated growth factors and local ischaemia–reperfusion cycles that can produce hyaline or cystic degeneration—clinically relevant when patients report acute focal pain in pregnancy or sudden change in prior stable symptoms. See the library overview of heavy menstrual bleeding for quantified bleeding assessment tools that pair well with fibroid work-up.

Symptomatology tracks more closely with location than with absolute size: submucosal lesions distort the endometrium and classically drive menorrhagia; intramural nodules increase uterine contractility and cramping; subserosal or broad-ligament masses generate pressure effects on adjacent viscera. Coexistent iron deficiency anaemia is common when heavy bleeding persists unchecked—nurses should pair menstrual history with objective haemoglobin trends and functional cues (syncope, dyspnoea on exertion, tachycardia).

The FIGO PALM-COEIN framework classifies structural causes of abnormal uterine bleeding under “L” for leiomyoma, with subclassification by endometrial interface (submucosal types 0–2), other intramural (3–8) and hybrid/transmural categories—radiology reports increasingly mirror this vocabulary. Teams use it to anticipate which symptoms dominate, whether hysteroscopic resection is feasible, and how myometrial incision planning might affect future obstetric risk.

↔On a small screen, swipe or scroll sideways to see the full table.

Many patients remain asymptomatic until imaging for another indication. When symptoms emerge, they cluster into bleeding, pain/pressure, reproductive compromise or pregnancy-related complications.

Typical presentations

• Prolonged or flooding menses, clots, cyclical anaemia symptoms.
• Pelvic heaviness, urinary frequency, sensation of incomplete emptying, constipation.
• Dyspareunia when cervical or broad-ligament masses distort fornices.

Atypical or high-risk patterns

• Non-cyclical bleeding or sudden change in established fibroid bleeding—think endometrial pathology.
• Acute abdomen with cardiovascular instability—consider torsion, degeneration with sepsis mimic, or ectopic pregnancy in reproductive-age patients.

Aetiology is multifactorial: genetic susceptibility, early menarche, nulliparity, obesity, vitamin D deficiency hypotheses, and red-meat–heavy dietary patterns recur in epidemiology. Black ethnicity associates with earlier onset, greater tumour burden and more symptomatic disease—equity-sensitive pathways should avoid dismissing pain or bleeding as “expected.”

Modifiable

• Weight management where adiposity amplifies oestrogenic milieu.
• Optimise blood pressure and glycaemic control when metabolic syndrome coexists.

Non-modifiable

• Family history of fibroids or early hysterectomy.
• Müllerian anatomy variants that distort cavity drainage.

Clinical assessment

Bimanual examination may reveal a mobile, irregularly enlarged, firm “lumpy” uterus, but sensitivity is limited in obesity or when the fundus is high. Always capture parity, contraception, fertility intent, anticoagulant use, prior fibroid therapy and caesarean scar history before procedural counselling.

Laboratory investigations

• FBC for anaemia and platelet trends; ferritin/B12/folate where indicated.
• Pregnancy test in any patient with uterine bleeding and intact reproductive organs.
• Coagulation screen when bleeding is acute and severe or anticoagulated.

Imaging

Transvaginal ultrasound delineates size, number, echotexture and vascular pattern; saline infusion sonography refines submucosal mapping when office hysteroscopy is deferred. MRI supports surgical planning, identifies adenomyosis overlap, and clarifies stalk anatomy before morcellation discussions. Hysteroscopy permits direct visualisation of cavity-distorting fibroids when concurrent endometrial pathology is suspected.

Criteria / scoring

Pictorial Blood Assessment Chart (PBAC) scores quantify menstrual blood loss for trials and clinic titration; integrate FIGO leiomyoma subclassification strings from imaging reports into pre-operative briefings so theatre teams share one mental model.

1. Detect & risk-stratify: heavy bleeding scores + haemoglobin + red-flag screen.
2. Image: transvaginal ultrasound first; MRI if mapping for myomectomy, morcellation risk discussion, or sarcoma concern.
3. Medical ladder: tranexamic acid ± NSAID window, hormonal suppression, iron repletion; GnRH analogues only with specialist oversight and bone-protection planning.
4. Procedural fork: hysteroscopic resection for type 0–2; myomectomy versus UAE versus hysterectomy based on fertility, fibroid map, comorbidity and patient preference.
5. Follow-through: 6–12 week post-procedure review with symptom scores and repeat haemoglobin; earlier if bleeding recurs.

↔On a small screen, swipe or scroll sideways to see the full table.

First-line medical management

• Tranexamic acid on heavy days; combine with scheduled ibuprofen when not contraindicated (see the ibuprofen monograph for contraindications).
• Combined hormonal contraception or progestogens to reduce menstrual volume; LNG-IUS where cavity allows (prescriber decision).
• Oral or IV iron for documented deficiency; align dosing with GI tolerance and haemoglobin targets.

Second-line / pre-operative bridging

• GnRH agonists/antagonists with add-back therapy for short windows to shrink uterine volume or stabilise haemoglobin—requires bone health and lipid surveillance.
• Selective progesterone receptor modulators where locally approved and monitored (hepatotoxicity programmes where mandated).

Procedural options

• Hysteroscopic myomectomy for submucosal types distorting cavity.
• Laparoscopic or open myomectomy for intramural/subserosal disease with fertility preservation goals.
• Uterine artery embolisation for uterus-preserving symptom control when fertility is not immediate priority.
• Hysterectomy remains definitive when bleeding or bulk remains disabling after less invasive options or when family is complete.

Special populations

• Pregnancy: multidisciplinary obstetric plans; counsel on degeneration pain versus other obstetric emergencies.
• Perimenopause: expect natural regression but continue red-flag surveillance until menopause confirmed.
• Anticoagulated patients: pharmacist-led review before NSAIDs; escalate procedural discussion earlier if haemoglobin cannot be maintained.

• Monitoring cadence: review symptoms and haemoglobin at 6–12 weeks after any therapy change; sooner if flooding or syncope.
• Referral thresholds: fibroids >3 cm with inadequate symptom control on optimised medical therapy (per NG88 nuance), hydronephrosis, recurrent admissions for anaemia, or fertility delay ≥12 months in age >35.
• Medication safety: document NSAID renal risk, thrombotic risk with hormonal options, and drug–drug interactions with GnRH therapies.
• MDT roles: interventional radiology for UAE counselling; anaesthesia for complex myomectomy blood-loss planning; haematology when coagulopathy suspected.

Bedside monitoring checklist

• Heart rate, blood pressure (orthostatic if symptomatic), SpO₂ if dyspnoeic.
• Quantified pads/tampons or PBAC score each visit.
• Pain score trend after embolisation or surgery; wound or lochia assessment postpartum if relevant.

• Iron deficiency and transfusion-dependent anaemia.
• Urinary tract infections or hydronephrosis from outlet obstruction.
• Infertility, miscarriage, malpresentation, postpartum haemorrhage, red degeneration.
• Rare leiomyosarcoma—maintain low threshold for imaging discordance with symptoms.

There is no proven primary prevention. Clinician-facing mitigation focuses on early detection of anaemia, weight and metabolic optimisation where feasible, and avoiding prolonged unopposed oestrogen exposure without progestogen opposition when prescribing hormones.

After menopause most fibroids regress; medical and minimally invasive options control symptoms in many premenopausal patients. Recurrence after myomectomy is possible—set expectations that surveillance ultrasound may be needed if fertility plans continue.

Translate imaging jargon into plain maps for patients while preserving accuracy in handovers: “submucosal 3 cm lesion indenting cavity” carries different counselling than “8 cm exophytic fundal mass.” Watch for subtle tachycardia or pallor in patients who minimise bleeding because of cultural taboos.

Pre-treatment

Verify pregnancy status, VTE risk, anticoagulation, and consent for fertility-sparing versus definitive surgery. Ensure iron studies and group & save when anaemia coexists with planned invasive steps.

Post-treatment

After UAE monitor analgesia ladders, antiemetics, urinary output and vaginal loss using MEOWS or local early-warning scores. Post-myomectomy watch for haemorrhage, ileus and DVT prophylaxis compliance.

Education & evaluation

Teach expected bleeding patterns after hormonal initiation, when to return for haemoglobin checks, and signs of infection. Evaluate understanding at each visit with teach-back.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response and matrix matching on the topic of leiomyoma bleeding, anaemia rescue, peri-embolisation monitoring and shared decision-making mapped to the Clinical Judgment Measurement Model (recognise cues → analyse cues → prioritise hypotheses → generate solutions → take actions → evaluate outcomes).